Kabazitaksel Ever Pharma

Cabazitaxel, the active ingredient in Kabazitaksel Ever Pharma, is a taxane presented as a solution for injection for intravenous use. It treats metastatic castration‑resistant prostate cancer in patients who have previously received docetaxel therapy and is marketed in the European Union. GNH USA supplies Kabazitaksel Ever Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Cabazitaxel is a taxane chemotherapy used in the management of advanced prostate cancer that has progressed despite prior therapy. - Metastatic castration‑resistant prostate cancer after docetaxel: extends overall survival in patients with disease progression. - Advanced prostate cancer with taxane resistance: provides an alternative chemotherapy option. - Prostate adenocarcinoma refractory to first‑line treatment: offers clinical benefit in later‑line settings.

Cabazitaxel may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced white blood cell count increasing infection risk. - Fatigue: persistent tiredness affecting daily activities. - Nausea and vomiting: gastrointestinal upset common during treatment. - Diarrhea: loose stools that may require supportive care. - Alopecia: hair loss that is usually reversible. - Peripheral neuropathy: tingling or numbness in extremities.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophils requiring urgent care. - Severe hypersensitivity reactions: rash, bronchospasm, or anaphylaxis. - Pulmonary toxicity: shortness of breath or interstitial lung disease. - Cardiac arrhythmias: irregular heart rhythms observed in some patients. - Life‑threatening infections: sepsis due to immunosuppression. - Death: rare but reported in heavily pre‑treated populations.

Before initiating Cabazitaxel therapy, clinicians should assess patient suitability and monitor for potential complications. - Hematologic monitoring: perform complete blood counts before each cycle to detect neutropenia. - Hepatic function: evaluate liver enzymes as cabazitaxel is metabolized hepatically. - Infection risk: avoid use in patients with active severe infections. - Contraception: advise both male and female patients of reproductive potential to use effective contraception during treatment and for a defined period after. - Cardiac assessment: consider baseline ECG in patients with known cardiac disease. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the vial.

Cabazitaxel can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase cabazitaxel exposure and toxicity. - Concurrent myelosuppressive agents (e.g., other chemotherapy, high‑dose steroids): heighten risk of severe neutropenia. - Live vaccines: immunosuppression can lead to uncontrolled infection.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce drug levels, lowering effectiveness. - Anticoagulants (e.g., warfarin, DOACs): monitor for bleeding as platelet counts may fall. - Diuretics: watch electrolyte balance, especially if renal function is impaired.